Baseline | 6 weeks | 6 months | P value | |
Clinical, functional, laboratory* | ||||
QOL score (median, range) | 48.0 (8.0–85.0) | 33.5 (0.0–73.0) | 23.5 (0.0–0.83) | 0.06 |
QRS (ms, median, range) | 162(120–212) | 145 (102–194) | 159 (112–214) | 0.02 |
6MWT (M, mean±SD) | 252.6±132.0 | 277.1±145.2 | 242.4±178.8 | 0.29 |
eGFR (ml/min/1.73 m2, median, range) | 52.0 (25.0–130.0) | 47.0 (24.0–105.0) | 52.7 (20.0–90.0) | 0.34 |
NT-pro-BNP (pmol/L, median, range) | 267.0 (75.0–4138.0) | 236.5 (27.0–3848.0) | 272.5 (15.0–1690.0) | 0.87 |
Body composition (median, range) | ||||
BMI (kg/m2) | 28.7 (22.4–41.9) | 28.5 (22.0–34.4) | 28.0 (22.4–35.7) | 0.39 |
Fat mass (kg)† | 31.4 (18.1–61.2) | 29.0 (18.9–61.2) | 29.1 (18.6–50.3) | 0.12 |
Relative fat mass† | 0.38 (0.23–0.54) | 0.34 (0.25–0.51) | 0.39 (0.28–0.52) | 0.09 |
Lean mass (kg)† | 52.3 (30.9–73.3) | 53.9 (31.9–75.0) | 50.5 (31.9–75.0) | 0.19 |
Waist circumference (cm)† | 98.2 (84.6–131.0) | 99.3 (76.0–119.4) | 100.1 (78.9–120.9) | 0.53 |
Echocardiography‡ | ||||
LVESV (mL, median, range) | 125.8 (62.9–268.7) | 112.7 (52.8–210.8) | 95.2 (57.8–315.6) | 0.26 |
LVESV_BSA(mL, median, range) | 58.9 (38.7–128.0) | 56.8 (28.2–118.7) | 49.5 (30.6–131.5) | 0.26 |
LVEF (%, median, range) | 25.6 (9.7–35.4) | 29.4 (13.6–43.6) | 32.7 (14.4–41.7) | 0.14 |
*Based on patients able to have clinical, functional and laboratory assessments (baseline=25, 6 weeks=24, 6 months=22),
†Based on participants able/available to have BOD-POD assessment (baseline=25, 6 weeks=23, 6 months=20).
‡Based non complete series of echocardiograms with biplane measurements.
BMI, body mass index; BOD POD, trade name of the device used; BSA, body surface area; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction ; LVESV, left ventricular end-systolic volume ; 6MWT, 6 min walk test; NT-pro-BNP, N-terminal probrain natriuretic peptide; QOL, quality of life.